» Articles » PMID: 24366376

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 2013 Dec 25
PMID 24366376
Citations 189
Authors
Affiliations
Soon will be listed here.
Abstract

Description: Update of the 2005 U.S. Preventive Services Task Force (USPSTF) recommendation on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

Methods: The USPSTF reviewed the evidence on risk assessment,genetic counseling, and genetic testing for potentially harmful BRCA mutations in asymptomatic women with a family history of breast or ovarian cancer but no personal history of cancer or known potentially harmful BRCA mutations in the family. The USPSTF also reviewed interventions aimed at reducing the risk for BRCA-related cancer in women with potentially harmful BRCA mutations, including intensive cancer screening, medications, and risk-reducing surgery.

Population: This recommendation applies to asymptomatic women who have not been diagnosed with BRCA-related cancer.

Recommendation: The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing. (B recommendation)The USPSTF recommends against routine genetic counseling or BRCA testing for women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes. (D recommendation).

Citing Articles

Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics: A Cluster Randomized Clinical Trial.

Swisher E, Harris H, Knerr S, Theoryn T, Norquist B, Brant J JAMA Netw Open. 2025; 8(3):e250185.

PMID: 40053353 PMC: 11889468. DOI: 10.1001/jamanetworkopen.2025.0185.


The breast cancer genetic testing experience: probing the potential utility of an online decision aid in risk perception and decision making.

Vaynrub A, Salazar B, Feng Y, West H, Michel A, Umakanth S BMC Cancer. 2025; 25(1):19.

PMID: 39773186 PMC: 11706066. DOI: 10.1186/s12885-024-13408-x.


Germline pathogenic variants among high hereditary risk patients with breast and ovarian cancer and unaffected subjects in Lebanese Arab women.

Moukadem H, Fakhreddine M, Assaf N, Safi N, Al Masry A, Al Darazi M World J Clin Oncol. 2024; 15(12):1481-1490.

PMID: 39720644 PMC: 11514371. DOI: 10.5306/wjco.v15.i12.1481.


Evidence-based advancements in breast cancer genetic counseling: a review.

Batool Z, Kamal M, Shen B Breast Cancer. 2024; 32(2):258-277.

PMID: 39688807 DOI: 10.1007/s12282-024-01660-9.


Prognostic implications of ductal carcinoma components in -positive breast cancer: a retrospective cohort study.

Yoon K, Kim E, Shin H Ann Surg Treat Res. 2024; 107(6):327-335.

PMID: 39669383 PMC: 11634396. DOI: 10.4174/astr.2024.107.6.327.